Blueprint Medicines (NASDAQ:BPMC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. “

Other analysts have also recently issued research reports about the stock. JMP Securities lifted their price target on shares of Blueprint Medicines from $88.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 11th. Wedbush reiterated an “outperform” rating and issued a $82.00 price target (up previously from $70.00) on shares of Blueprint Medicines in a report on Monday, November 6th. DA Davidson began coverage on shares of Blueprint Medicines in a report on Friday, September 29th. They issued a “buy” rating and a $90.00 price target on the stock. ValuEngine cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Goldman Sachs Group lifted their price target on shares of Blueprint Medicines from $82.00 to $99.00 and gave the company a “buy” rating in a report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $84.10.

Blueprint Medicines (NASDAQ:BPMC) opened at $79.24 on Thursday. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.02. Blueprint Medicines has a fifty-two week low of $31.35 and a fifty-two week high of $92.00. The stock has a market cap of $3,398.03, a P/E ratio of -23.24 and a beta of 1.29.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.06). Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The firm had revenue of $8.07 million during the quarter, compared to the consensus estimate of $5.35 million. During the same quarter in the prior year, the business posted ($0.62) EPS. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. research analysts forecast that Blueprint Medicines will post -3.75 EPS for the current fiscal year.

In other Blueprint Medicines news, CEO Jeffrey W. Albers sold 30,000 shares of the firm’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $70.31, for a total transaction of $2,109,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Marion Dorsch sold 18,334 shares of the firm’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total value of $1,199,960.30. Following the transaction, the insider now directly owns 18,334 shares of the company’s stock, valued at approximately $1,199,960.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,334 shares of company stock worth $3,978,160. 3.40% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the business. Rockefeller Financial Services Inc. purchased a new position in Blueprint Medicines during the third quarter valued at $160,000. Ameritas Investment Partners Inc. lifted its position in Blueprint Medicines by 68.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,391 shares during the period. Fred Alger Management Inc. purchased a new position in Blueprint Medicines during the second quarter valued at $203,000. SG Americas Securities LLC lifted its position in Blueprint Medicines by 23.3% during the second quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 778 shares during the period. Finally, Turner Investments LLC purchased a new position in Blueprint Medicines during the third quarter valued at $209,000. 83.54% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/blueprint-medicines-bpmc-stock-rating-lowered-by-zacks-investment-research/1807934.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.